Tags: alprazolam, case letters, confusion, conscious organizations, consistency, drug names, fda, ismp, lettering, lorazepam, medication, metformin, metronidazole, pairs, reduction strategy, safe medication practices, tall man, ups,
Institute for Safe Medication Practices
FDA and ISMP Lists of
Look-Alike Drug Name Sets With Recommended Tall Man Letters
he sets of look-alike drug names in the Tables below have been One of the difficulties with the use of tall man letters is the lack of
T modified using "tall man" letters to help draw attention to the
dissimilarities in their names. Several studies have shown that
scientific evidence regarding which name pairs would most benefit from
this error-reduction strategy as well as which letters to present in
highlighting sections of drug names using tall man (mixed case) letters uppercase. Until further evidence is available, ISMP suggests that the
can help distinguish similar drug names,1 making them less prone to tall man lettering scheme provided in these Tables be followed to
mix-ups.2-3 ISMP, FDA, The Joint Commission, and other safety- promote consistency.
conscious organizations have promoted the use of tall man letters as
one means of reducing confusion between similar drug names. Table 2. ISMP List of Additional Drug Names with Tall Man Letters
Table 1 provides a list of FDA-approved established drug name sets ALPRAZolam - LORazepam metroNIDAZOLE metFORMIN
with recommended tall man letters, which were first identified during
amLODIPine aMILoride morphine HYDROmorphone
the FDA Name Differentiation Project (www.fda.gov/CDER/Drug/
MedErrors/nameDiff.htm). azaCITIDine azaTHIOprine NexIUM* NexAVAR*
Table 2 provides a list of additional drug name sets with recommenda- ceFAZolin cefTRIAXone niMODipine NIFEdipine
tions from ISMP regarding the use and placement of tall man letters. CeleBREX* CeleXA* NovoLOG* NovoLIN*
This is not an official list approved by FDA. It is intended for voluntary
use by healthcare practitioners and drug information vendors. Any chlorproMAZINE chlordiazePOXIDE OXcarbazepine carBAMazepine
product label changes by manufacturers require FDA approval. CISplatin CARBOplatin oxyCODONE OxyCONTIN*
clonazePAM cloNIDine PARoxetine FLUoxetine
Table 1. FDA-Approved List of Established Drug Names with Tall Man Letters
clonazePAM - LORazepam PENTobarbital PHENobarbital
acetoHEXAMIDE - acetaZOLAMIDE hydrALAZINE hydrOXYzine
cloNIDine KlonoPIN* PriLOSEC* PROzac*
buPROPion - busPIRone
DACTINomycin DAPTOmycin QUEtiapine OLANZapine
medroxyPROGESTERone
chlorproMAZINE chlorproPAMIDE methylPREDNISolone ePHEDrine EPINEPHrine quiNINE quiNIDine
methylTESTOSTERone
clomiPHENE clomiPRAMINE fentaNYL SUFentanil riTUXimab inFLIXimab
cycloSPORINE cycloSERINE niCARdipine NIFEdipine FLUoxetine DULoxetine SandIMMUNE* SandoSTATIN*
guanFACINE guaiFENesin SEROquel* SINEquan*
DAUNOrubicin DOXOrubicin predniSONE prednisoLONE
HumaLOG* HumuLIN* Solu-MEDROL* Solu-CORTEF*
dimenhyDRINATE diphenhydrAMINE sulfADIAZINE sulfiSOXAZOLE
HYDROcodone oxyCODONE SUMAtriptan sitaGLIPtin
DOBUTamine DOPamine TOLAZamide TOLBUTamide
IDArubicin DOXOrubicin tiZANidine - tiaGABine
glipiZIDE glyBURIDE vinBLAStine vinCRIStine INVanz* AVINza* traZODone - traMADol
References: 1) Filik R, Purdy K, Gale A, Gerrett D. Drug name confusion: eval- LaMICtal* LamISIL* TRENtal TEGretol*
uating the effectiveness of capital ("Tall Man") letters using eye movement data.
lamiVUDine lamoTRIgine ZyPREXA* ZyrTEC*
© ISMP 2008
Social Science & Medicine 2004;59(12):2597-2601. 2) Filik R, Purdy K, Gale A,
Gerrett D. Labeling of medicines and patient safety: evaluating methods of
reducing drug name confusion. Human Factors 2006;48(1):39-47. 3) Grasha A.
Cognitive systems perspective on human performance in the pharmacy: impli- * Brand names always start with an uppercase letter. Some brand names incor-
cations for accuracy, effectiveness, and job satisfaction. Alexandria (VA): porate tall man letters in initial characters and may not be readily recognized as
brand names. An asterisk follows all brand names in Table 2.
NACDS; 2000 Report No. 062100.
© ISMP 2008. Permission is granted to reproduce material for internal newsletters or communications with proper attribution. Other reproduction
is prohibited without written permission from ISMP. Report actual and potential medication errors to the Medication Errors Reporting Program Institute for Safe
(MERP) via the Web at www.ismp.org or by calling 1-800-FAIL-SAF(E). Medication Practices
www.ismp.org